Researchers explore alternative strategies like cancer-selective inhibitors, MGMT expression downregulation, autoantibodies, and localized drug delivery to attenuate MGMT activity and minimize normal cell exposure [13,24,37,39]. The gene discussed is MGMT; the disease is cancer.